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Abstract 
The history began in the 19
th
 century with Ascanio Sobrero (1812-1888), the discoverer of glycerol trinitrate 
(nitroglycerine, NTG), and with Angelo Angeli (1864-1931), the discoverer of sodium trioxodinitrate 
(Angeli’s salt). It is likely that Angeli and Sobrero have never met, but their two histories will join each other 
more than a century later. In fact, it has been discovered that both NTG and Angeli’s salt are able to induce 
a preconditioning effect. Since NTG has a long history as an antianginal drug its new discovered property as 
a preconditioning agent has been also tested in humans. Angeli’s salt properties as preconditioning and 
inotropic agent have been tested in animals only so far. 
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The professor of chemistry Alfonso Cossa (1833-1902) was the successor of Ascanio Sobrero at the 
University of Torino, Italy. Angelo Angeli was one of the best pupils of Cossa and Cannizzaro. The latter was 
somehow involved in the story that saw Sobrero against Piria in a series of battles for university chair 
assignments around 1855. At the end, Piria settled in Torino and Cannizzaro in Genoa, against the wishes of 
Sobrero. However, in all this flurry of fights between academics there are not records of a meeting between 
Angeli and Sobrero. 
In this short narrative review, we will see that the history has begun in the 19
th
 century with Ascanio 
Sobrero and with Angelo Angeli, who discovered nitroglycerine and sodium trioxodinitrate, respectively, 
and we will see that the two histories will join in the 20
th
 century with the discovery of some common 
physiological mechanisms of the two compounds (Fig. 1). 
 
Nitroglycerine (NTG) was discovered in 1847 by Sobrero working at the University of Torino. Sobrero was 
born in Casale Monferrato (Alessandria, Piedmont) on the12
th
 October 1812. He had gotten the degree in 
Medicine at the “Università di Torino” in 1833. His interest for chemistry was due to the uncle, the general 
Carlo Sobrero. Ascanio Sobrero worked as an assistant to professor Pelouze in Paris and then in 1845 
became professor of chemistry in Torino
1
. He initially considered nitroglycerine to be far too dangerous to 
be of any practical use. Sobrero is quoted to have said: "When I think of all the victims killed during 
nitroglycerine explosions, and the terrible devastation that has been committed, I am almost ashamed to 
admit to be its discoverer. The worst is that these crimes will continue to occur in the future…. because of 
the wickedness of human soul". Another of Pelouze's pupils was the young Alfred Nobel, who took the 
knowledge back to the “Nobel family's defunct armaments factory”, and began experimenting with the 
compound around 1860. Although Nobel always acknowledged and honoured Sobrero as the man who had 
discovered nitroglycerine, Sobrero was dismayed both by the uses to which the terrible power of the 
explosive had been put, and by the fame and fortune accorded to Nobel because of it. He felt he had been 
subject to an injustice. Sobrero also discovered the photochemical oxidation of hydrate of trementine of 
pinol, the so called “Sobrerolo”, which is called in that way in his honour. Sobrerolo is still used as 
respiratory stimulant. He was a member of the “Accademia delle Scienze” of Torino. He died in Torino on 
26
th 
December 1888. 
 
History does not record why NTG was first applied to the relief of human suffering. Sobrero tasted the 
compound and found that “a very minute quantity upon the tongue produces a violent headache”. It fell, 
however, to Guthrie in 1859 to have the first note on the fact that nitrite of amyl caused flushing of the 
face. Guthrie proposed that the compound could be used as a resuscitative
1,2
. However, it was Lauder 
Brunton
3
 to first use nitrite of amyl for the relief of angina pectoris in 1867. Brunton wrote: “to my delight 
the experiment proved a complete success… the patient’s face became flushed, the pulse, instead of being 
small and thready, became full and bounding, and the (anginal) pain almost instantaneously disappeared” 
3
. Brunton also noted that NTG had an action very similar to amyl nitrite but he hesitated to give it to 
patients as he “used to get such an awful headache from working with it”
3
, an obvious allusion to cerebral 
vasodilatation and increase in cerebral blood flow.  
After Brunton had first recommended nitrate therapy against angina in the Lancet3 the efficacy of 
nitrates in coronary artery disease has been well established. There is no doubt on this: NTG 
remains the treatment of choice for relieving angina1,4-9. 
More recently, apart from preload reduction and coronary vasodilatation, a number of beneficial effects of 
NTG and other nitric oxide (NO) donors have emerged, such as improved endothelial function
4-6
, inhibition 
of platelet aggregation and cyclic flow variations
7
, improvement of the efficiency of energy use
8
, and 
preservation of contractile function during myocardial ischemia/reperfusion (I/R)
9,10
. 
However, despite the large body of research in this field and a wide clinical use of nitrates, it is noteworthy 
that about 165 years after Sobrero first synthesized nitroglycerine, we remain with at least four questions 
of fundamental importance: 1) How do nitrates work? 2) Why do nitrates stop working upon continuous 
administration? 3) Do nitrates induce a long-term effect? and 4) What are the long-term effects of nitrate 
therapy on clinical outcome? Interestingly, these questions, which appear to be closely interrelated, are still 
without definitive answers. 
 
In this report we will not try to definitely answer to these issues, but analyze some studies related with 
these questions. We will mainly consider those studies that have shown a “new mechanism” of NTG as 
trigger of cardioprotection (i.e. preconditioning effects), as this particular effect represents the "trait 
d'union" with the discovery of Angeli’s salt by Angelo Angeli. In particular we will consider how about 30 
years ago a new interest on these compounds restarted.  
 
Ignarro et al.
11
 apparently answered the first of the above posed questions. They hypothesized that NO 
release mediates the effects of nitrates. This is true, but about 60% of the arterial vasodilatatory effect of 
nitroglycerine is, at least in vitro, attributed to the opening of potassium channels in endothelial cells
5,6,12
. 
Nitric oxide itself may act as potassium channel opener
13
. Recent observations also suggest that under 
certain circumstances nitroglycerine might not act through NO release
14
. 
Nevertheless, following the discovery of endothelium derived relaxing factor (EDRF)
15
, and its identification 
as NO
16,17
 there was a revival of interest on nitrite-containing compounds. Afterward thousands of papers 
have been published on these vasodilator compounds. It is now clear that NO may be produced by 
constitutive enzymes, namely endothelial NO synthase (eNOS) and neuronal NOS (nNOS), and inducible 
enzyme (iNOS), as well as by non-enzymatic processes
18-22
.  
The importance of NO in biology has been highlighted in 1992 by the Science magazine which defined nitric 
oxide the molecule of the year, and in 1998 when Furchgott, Ignarro and Murad were awarded with the 
Nobel Prize in ‘‘Physiology or Medicine’’ for their pioneering research in this field.  
After about 160 years from its discovery, studies have identified “long-term”/“new mechanism” of action 
for NTG in animals
13,19
 and humans
10,23-25
. The works of Pagliaro and co-workers
13,24,26
 on preconditioning 
have been performed at the University of Torino: “history repeats itself”.  
To better understand this relatively “new mechanism” we should spend some words on the definition of 
preconditioning (PC). The stimulus to induce PC consists in a series of brief (a few minutes) ischemia and 
reperfusion. Originally described as an immediate adaptation of the heart to brief sub lethal ischemia
27
, it is 
now recognized that ischemic PC consists of two distinct phases: an early phase and a late phase of 
protection, which can be also induced pharmacologically. The early phase occurs immediately after the PC 
stimulus and induces robust protection. The early PC is short lasting (1 to 3 hours). This short period of 
efficacy limits its clinical relevance. In contrast, the late phase of PC develops 12 to 24 hours after the initial 
stimulus and lasts 3 to 4 days
13,19.
 Unlike the early phase, the late phase of ischemic PC protects not only 
against myocardial infarction but also against myocardial stunning
13,19
. The late phase of PC is particularly 
interesting because it provides a long lasting and robust protection. Also angina can induce protection 
against myocardial infarction in adult, but this possibility is lost in elderly patients
28,29
. 
Besides the short period of ischemia, several other stimuli, including NO donors, may trigger PC. Because of 
this fact a considerable interest has been focused on PC and its clinical exploitation. In particular, the 
possibility to induce pharmacological PC makes this phenomenon really interesting from the viewpoint of 
translational medicine from bench to bedside, especially in the case of programmed intervention which can 
jeopardize the heart. The interrelation between ischemic preconditioning, NTG and aging heart has been 
explored and demonstrated by several groups, in animals and human studies
28,30-41
. In preconditioning a 
pivotal role is played by reactive oxygen species (ROS) production by mitochondria and NO formation by 
enzymatic (NOS) and non-enzymatic origin, which participate to the cardioprotection in the early stage and 
to the induction of enzyme expression, such as iNOS, cyclooxygenase (COX)-2 and superoxide dismutase 
(SOD), in the late phase of protection. In this context, particularly important is the role of mitochondrial 
permeability transition pore (mPTP). It seems that mPTP opening is a two-edged sword, with both 
protective (transient opening) and deleterious (prolonged opening) actions in both the pre- and 
postischemic phases
22,42
. In particular, it has been suggested that a transient mPTP opening mediates 
preconditioning-induced protection via formation of small bursts of ROS
43 
.. Importantly, it has been 
observed in humans that NTG also causes preconditioning-like improvement of flow-mediated dilation via 
ROS production and mPTP opening
44
.  
The role of mitochondria, ROS signaling, and NO from eNOS and iNOS in the early and late NTG 
preconditioning has been studied by several groups (the reader is kindly redirected to extensive reviews on 
this topic; e.g,
5,13,19,21,22,30,37,45
). 
Of note, GRACE investigators have shown using data from 52.693 patients that chronic nitrate therapy is 
associated with better presentation and evolution of acute coronary syndromes
32
. This observation might 
represent an answer to the above questions marked with number 3 and 4. 
Recent, interesting experimental studies that support beneficial effects of chronic NO bioavailability are 
those in which Bolli and coworkers performed either the gene transfer of iNOS
46
 or the cardiomyocyte-
restricted overexpression of extracellular SOD (ecSOD)
47
, in mice. With iNOS gene transfer they observed 
long-term (1 year) cardioprotection against I/R injury, without negative functional consequences
42
. With 
cardiac-specific ecSOD overexpression they observed the attenuation of the levels of ROS by increased NO 
availability in response to I/R and the protection against reperfusion injury
47
. However caution must be 
used, in fact, for instance, iNOS expression in peripheral blood cells may mediate myocardial I/R injury
48
. 
These studies pave the way for further pre-clinical testing of gene therapy. 
The role of NO as a trigger and mediator of PC is not entirely clear. Although it is not clear whether or not 
endogenous NO is less important in early preconditioning’s protection against myocardial infarction
9,39,49
, 
exogenous NO triggers early PC mainly through a free radical mechanism
26,39
. Yet, nitric oxide acts as a 
trigger and mediator in delayed preconditioning’s protection against both myocardial infarction and 
stunning
13,19,26
. Importantly, nitroglycerine induces delayed preconditioning against myocardial stunning 
through a protein kinase C–dependent pathway
40,50
. The study of Banerjee et al.
40
 and other studies on the 
role of NO in ischemic preconditioning have recently confirmed in animals and humans the possibility to 
induce late PC with NTG
23,24
. The ability of NO-releasing agents such as nitrates to mimic the late phase of 
ischemic PC supports the possibility of novel clinical applications of these drugs. We demonstrated that 
NTG-induced preconditioning can positively affect hemodynamics during subsequent exercise in patients 
suffering from stable angina even 48 hours later from NTG administration. In fact, we found that heart rate, 
stroke volume, myocardial contractility and cardiac output at peak exercise were improved during the late 
PC period induced by the transdermal administration of NTG
24
. Importantly, a late PC-mimetic effect that 
improved exercise capacity during exercise and mitigated the ECG manifestations of ischemia was also 
observed 48 hours after the ischemia elicited by an exercise test
23
. To the best of our knowledge Crisafulli 
et al.
24
 were the first that analyzed global performance in the same subjects in which was measured ECG 
during the late PC period induced by NTG or exercise. A positive effect of tonically released NO on cardiac 
function in healthy humans has also been suggested by Rassaf et al.
51
. These authors reported that 
inhibition of endogenous NO release reduced, whereas restoration with a NO donor, S-nitrosoglutathione, 
increased heart function. 
The precise mechanism by which NTG and NO protect against ischemia remains to be elucidated, but it 
appears to involve the activation of soluble guanylate cyclase (sGC), given that both the alleviation of 
stunning and the reduction in infarct size are abrogated by the selective sGC inhibitor ODQ. It has been also 
suggested that NO protects by up regulating and activating COX-2
9,41
. The opening of KATP channels by 
NTG
12,13
 can also play a role in its capacity to induce cardioprotection. S-Nitrosylation of proteins may play 
also a pivotal role in cardioprotection
21,22,45
.  In fact, much of NO-triggered signaling appears to result from 
S-Nitrosylation, including the regulation of vascular sGC
52
. The role for S-Nitrosylation in altering protein 
localization has not been well studied in heart. However, S-Nitrosylation could protect by influencing the 
activity of mitochondrial proteins and other cell organelles. It has also been shown in other cell types to 
alter the localization of proteins and thereby altering cell death signaling. S-Nitrosylation can also protect 
by shielding thiol groups from oxidation and thereby allowing more rapid recovery of protein function in 
post-ischemic phase. Whether S-Nitrosylation mediates protection by the sum of these multiple pathways 
or whether S-Nitrosylation of one or two proteins is of primary importance in mediating cardioprotection is 
unclear at this time
21,22
. 
The prognosis of long-term nitrate therapy is complicated by the tolerance phenomenon and the potential 
induction of endothelial dysfunction mainly by ROS-stress, which may have negative prognostic 
implications. Already Brunton noted that if NTG was used for a long time as relief of angina pain “…the dose 
requires to be increased before the effect is produced…”, for instance the first reference to what we now 
refer to as nitrate tolerance
3
. The nitrate tolerance is also connected with the well known phenomena of 
Monday disease and nitrate-withdrawal/overcompensation by Sunday Heart Attacks observed in workers in 
the explosives industry, in the nineties. The history of these phenomena is elegantly reported in the review 
of Marsh and Marsh
1
. 
In the long run efficacy of nitrates in most patients is potentially limited both by de novo vascular and 
platelet hypo-responsiveness (referred to as nitrate resistance) and by the potential development, during 
chronic nitrate therapy, of an attenuation of such responses, termed true nitrate tolerance and pseudo-
tolerance (see Münzel et al.
54
 for a review). Many studies in the near past considered the tolerance 
phenomenon of NTG in an attempt to respond to the above question marked with number two (Why do 
nitrates stop working upon continuous administration?). Some recent studies, including those of Münzel & 
Gori and coworkers, started to solve this complicated issue
53-57
. These studies suggest new mechanisms to 
explain nitrate tolerance, provide evidence for different potencies among nitrates to produce tolerance and 
demonstrate in clinical investigations that tolerance might be reduced by addition of hydralazine or folic 
acid
54-57
. Beneficial effects in attenuating nitrate tolerance are also observed with therapy with the 
angiotensin-AT1 receptor blocker telmisartan and the statin atorvastatin, which also prevents nitroglycerin-
induced endothelial dysfunction in healthy humans
56,57
. In particular, it has been suggested that a role is 
played by reactive oxygen species and protein kinase C activation in developing nitrate tolerance
54
. Also 
adverse phosphorylation and S-Glutathionylation of endothelial nitric oxide synthase have been involved in 
tolerance development
58,59
. 
Of note, also the protective effect of acute NTG may be attenuated by daily administration of this drug. 
However, pentaerythrityl tetranitrate (PETN), which is an organic nitrate with intrinsic antioxidant 
properties, may induce preconditioning-like effects against post-ischemic endothelial dysfunction, which 
are maintained even after PETN prolonged administration in humans. Such a difference has been attributed 
to differential effects of the two compounds on the activity of mitochondrial aldehyde dehydrogenase, an 
enzyme also involved in ischemic- and nitrate-induced preconditioning
60,61
.  
In addition, a variety of studies have suggested that nitrates are endowed with antiplatelet, antioxidative, 
antiadhesive and antiproliferative effects. These effects might also be useful in coronary artery disease 
(CAD) patients as in vivo animal experiments provided evidence that therapy with different nitrates could 
reduce the progression of atherosclerosis and endothelial dysfunction
6,58
. Finally, a large clinical trial with 
the potassium channel opener and nitrovasodilator, nicorandil, has shown beneficial effects in CAD 
patients, who had been taking oral nicorandil during the followup
59
.  
 
Thanks to preconditioning, the history of NTG, which started with Sobrero, has been joined to the history of 
so-called Angeli’s salt (Na2N2O3; sodium trioxodinitrate), which was originally synthesized in the late 1800s 
by Angelo Angeli, another Italian chemist
62,63
. 
Angeli was born in Tarcento (Udine), on 20
th
 August 1864. Since when he was young he demonstrated a 
remarkable interest for chemistry also encouraged by his uncle Giovanni Carnelutti (1850-1901), pupil of 
Cannizzaro. Because of his bashful character Angeli did not attend meetings and did not talk in front of 
people. This may be one of the reasons why there is no news of a meeting between Angeli and Sobrero, 
even though Angeli was a member of the “Accademia Nazionale delle Scienze” as Sobrero. This shyness did 
not help Angeli to gain honour in the Italian academy. However, Willstaetter (1872-1942), Nobel Prize in 
1915, wrote about Angeli: “The Angeli’s work is the best among those of Italian chemists both for originality 
and value”. Angeli was the father of the so-called “Theorie der Vernachlässigung des Benzolkerns” (i.e. The 
theory of the neglected benzoic nucleus). He also studied the relation between compounds structure and 
olfactory properties
57
. Angelo Angeli died on 31
st
 May 1931.  
 
Recently, Angeli’s salt has regained the interest of biologists, although there are not yet human in vivo data 
for this substance. At present Angeli’s salt is the only compound available that spontaneously releases 
nitroxyl (HNO, a nitric oxide sibling also known as nitrosyl hydride) under physiological conditions
64,65
. 
Clearly Angeli’ salt is not a NO donor, but it is a HNO donor which has distinct effects. Sulfohydroxamic acid 
derivatives such as Piloty’s acid also spontaneously release HNO, but only under basic conditions, and it 
undergoes rapid oxidation yielding NO rather than HNO
64,65
. It has been reported that HNO elicits 
vasorelaxation in both bovine intrapulmonary artery and the rabbit aorta by a sGC-dependent pathway
64,65
. 
It is now clear that the thiol-donating agent L-cysteine can discriminate the vasodilatative profile of HNO 
from that of NO or nitrosothiols: effects of HNO, donated by Angeli’ salt, can be blocked by this agent, 
whereas the action of NO, donated by NO-donors, is potentiated
66
. 
Recently, a comparative study with Angeli’s salt and DEA/NO (a pure NO-donor) determined that equimolar 
HNO released by Angeli’s salt appeared to be a more effective preconditioning agent than NO
26
. In fact, 
post-ischemic (2 h) contractility was similarly improved with ischemic PC or pre-exposure to Angeli’s salt, 
compared with control or DEA/NO-treated hearts. Infarct size and lactate dehydrogenase release were also 
significantly reduced in ischemic PC and Angeli’s salt groups, whereas DEA/NO was less effective in limiting 
necrosis
26
.  
Recently, Paolocci and co-workers
67-72
 have shown that the nitroxyl donor Angeli’s salt appears to be very 
good candidate to treat failing hearts that are characterized by pressure overload, poor contractile function 
and delayed relaxation. In fact when it was administered to normal, conscious dogs and those with heart 
failure an enhancement of heart contractility and lusotropy were observed together a vasodilator 
action
63,67
. The complexity of the mechanisms of the beneficial cardiac effects of HNO has also been 
examined in cardiomyocytes. It seems that the main mechanism of action of HNO uses its thiophylic nature 
as a vehicle to interact with redox targets such as cysteines, which are located in key components of the 
cardiac electromechanical machinery ruling myocardial function
70,71
. 
Calcitonin gene-related peptide (CGRP) does not account for direct HNO-evoked positive inotropy-lusitropy. 
However, HNO-induced CGRP release might play an indirect role in improving cardiac function and may, in 
part, explain HNO-induced vasodilation
72,73
. In the cardiovascular system, CGRP is a potent vasodilator and 
induces positive cardiac inotropy in several species including humans
74
. HNO is also an effective inhibitor of 
human platelet aggregation in vitro
75
. 
New nitroxyl donors not only would confirm that the physiological effects seen with Angeli's salt are truly 
due to HNO, but they also would help researchers determine if the rate of HNO release had any effect on 
the resulting physiological response. Of course, to propose HNO donors for the treatment of heart failure, 
they need to be tested in the long terms and in humans. 
Concluding remarks 
We owe a great debt to Sobrero, Angeli, Brunton and the 1998 Nobel laureates for their discoveries. 
Nowadays NTG is scarcely used as an explosive, but remains the drug of choice for angina relief and its new 
property as preconditioning agent make it a very interesting compound.  
Nitrates are part of combined modality therapy for myocardial ischemia, chest pain, hypertension and  
heart failure in patients with acute coronary syndrome. Nevertheless, the use of NTG prolonged 
administration is steadily declining, and it is mainly administered in settings of refractory angina
61
. The use 
of new methods of administration of nitrates, such as atypical therapeutic schemes able to determine 
preconditioning-like effects and the association with antioxidants (e.g., hydralazine) capable of modifying 
the tolerance and endothelial dysfunction might open new perspectives for reconsidering the use of NTG in 
the long term. 
Angeli’ salt with its inotropic and preconditioning properties has opened a new frontier for the research on 
this field. Of course, because of its clinical use, more is known about NTG than Angeli’ salt, but for instance 
working with these two compounds which have similar and different features we can understand more 
about their mechanisms of action and their usefulness. In fact, we must stress that despite about 165 years 
of clinical practice and research, nitrates remain intriguing drugs, whose mechanisms of action still need 
investigation. We hope the present article will be a stimulus for further discussions and research.  
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FIGURE LEGEND 
Figure 1. Time line shows the chain of some of the researches that led to an understanding of nitroglycerine and 
Angeli’salt as cardiotropic agents. EDRF= endothelium-derived relaxing factor. 
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